Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02241720 · ClinicalTrials.gov registry record · Phase 2
Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
A Phase 2 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02241720 is a Phase 2 study that was terminated before completion, run by University of Utah. The registered enrollment target is 5 participants.
The verdict
NCT02241720, a Phase 2 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Regorafenib as a Second Line Single Agent in the Treatment of Metastatic or Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
Interventions
- DRUG regorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02241720
The ClinicalTrials.gov registry entry for NCT02241720 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which regorafenib is the first listed.
NCT02241720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02241720 about?
NCT02241720 is a clinical study titled "Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers". Regorafenib as a Second Line Single Agent in the Treatment of Metastatic or Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
What is the current status of trial NCT02241720?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2014-05. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02241720?
The interventions under investigation include: regorafenib (DRUG).
Who is sponsoring clinical trial NCT02241720?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.